You are here: Industry Insights > Orchard

News List

NICE ‘no’ for Orchard Therapeutics’ gene therapy Libmeldy pharmatimes
July 13, 2021
The National Institute for Health and Care Excellence (NICE) has announced that it does not recommend Orchard Therapeutics’ gene therapy Libmeldy for the treatment of metachromatic leukodystrophy (MLD) in children.
Orchard Therapeutics Announces OTL-200 Granted RMAT Designation americanpharmaceuticalreview
January 21, 2021
Orchard Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OTL-200, an investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the ...
Orchard Announces Global License Agreements for Stable Cell Line Technology from GSK americanpharmaceuticalreview
July 23, 2020
Orchard Therapeutics announced the company has entered into two worldwide royalty-bearing license agreements with GlaxoSmithKline (GSK).
Orchard Therapeutics Announces MAA Filing of Metachromatic Leukodystrophy Treatment americanpharmaceuticalreview
December 30, 2019
Orchard Therapeutics announced the European Medicines Agency (EMA) has validated the company’s Marketing Authorization Application (MAA) for OTL-200 ...
Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine b3cnewswire
January 23, 2019
Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies....
PRIME status for Orchard’s gene therapy pharmatimes
October 11, 2018
The European Medicines Agency has granted Orchard Therapeutics’ experimental gene therapy OTL-300 PRIME designation as a potential treatment for the most severe form...
GSK hands rare disease gene therapies over to Orchard pharmatimes
July 17, 2018
Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies.
Orchard Therapeutics Announces Appointments of Marc Dunoyer and Charlie Rowland to Board of Directors b3cnewswire
June 20, 2018
Orchard Therapeutics, a leading commercial stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the appointments of Marc Dunoyer and Charlie Rowland to its board of dir
GW Pharma and Orchard biggest UK biotech fundraisers in Q1 pharmaphorum
April 11, 2018
The UK biotech sector has enjoyed a ‘solid start’ in early 2018, with GW Pharma and Orchard Therapeutics dominating the funding raised.
Extension of Orchard’s Collaboration with Manchester University to Include Sanfilippo Syndrome Type biospectrumasia
November 28, 2017
Orchard is dedicated to transforming the lives of patients with rare disorders through innovative gene therapies.

Previous page 1 2 Next page